Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Karukonda P, Odhiambo D, Mowery YM (2022) Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Mol Carcinog 61(2):225–238

Article  CAS  PubMed  Google Scholar 

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Prim 6(1):92

Article  PubMed  Google Scholar 

Chow LQM (2020) Head and Neck Cancer. Longo DL, editor. N Engl J Med. ; 382(1):60–72

Gorecki L, Andrs M, Rezacova M, Korabecny J (2020) Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol Ther, vol 210. Elsevier Inc., p 107518

Faulhaber E-M, Jost T, Symank J et al (2021) Kinase inhibitors of DNA-PK, ATM and ATR in combination with Ionizing Radiation can increase Tumor Cell Death in HNSCC cells while sparing normal tissue cells. Genes (Basel) 12(6):925

Article  CAS  PubMed  Google Scholar 

Scheper J, Hildebrand LS, Faulhaber EM et al (2022) Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in Melanoma cells with low toxicity to healthy fibroblasts. Strahlentherapie Und Onkol.

Fokas E, Prevo R, Pollard JR et al (2012) Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis Nature Publishing Group 3(12):e441–e410

Article  CAS  Google Scholar 

Tu X, Kahila MM, Zhou Q et al (2018) ATR inhibition is a Promising Radiosensitizing Strategy for Triple-negative Breast Cancer. Mol Cancer Ther 17(11):2462–2472

Article  CAS  PubMed  PubMed Central  Google Scholar 

ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=berzosertib

Shapiro GI, Wesolowski R, Devoe C et al (2021) Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer Springer US 125(4):520–527

Article  CAS  Google Scholar 

Terranova N, Jansen M, Falk M, Hendriks BS (2021) Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. Cancer Chemother Pharmacol. Springer Berlin Heidelberg; ; 87(2):185–196

Middleton MR, Dean E, Evans TRJ et al (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. Br J Cancer Springer US 125(4):510–519

Article  CAS  Google Scholar 

Yap TA, O’Carrigan B, Penney MS et al (2020) Phase I Trial of First-in-class ATR inhibitor M6620 (VX-970) as Monotherapy or in combination with carboplatin in patients with Advanced Solid tumors. J Clin Oncol 38(27):3195–3204

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomas A, Redon CE, Sciuto L et al (2018) Phase I study of ATR Inhibitor M6620 in Combination with Topotecan in patients with Advanced Solid tumors. J Clin Oncol 36(16):1594–1602

Article  CAS  PubMed  Google Scholar 

Kuess P, Bozsaky E, Hopfgartner J, Seifritz G, Dörr W, Georg D (2014) Dosimetric challenges of small animal irradiation with a commercial X-ray unit. Z Med Phys Elsevier B V 24(4):363–372

Article  Google Scholar 

Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc Nature Publishing Group 1(5):2315–2319

Article  CAS  Google Scholar 

Haas M, Lenz T, Kadletz-Wanke L, Heiduschka G, Jank BJ (2022) The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines. Invest New Drugs 40(4):700–708

Article  CAS  PubMed  PubMed Central  Google Scholar 

MRI Wound Healing Tool. Available from: https://github.com/MontpellierRessourcesImagerie/imagej_macros_and_scripts/wiki/Wound-Healing-Tool

Ianevski A, Giri AK, Aittokallio T (2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res 50(W1):W739–W743 Oxford University Press

Article  CAS  PubMed  PubMed Central  Google Scholar 

SynergyFinder. Available from: https://synergyfinder.fimm.fi/

Chou T-C, Theoretical Basis (2006) Experimental design, and Computerized Simulation of synergism and antagonism in Drug Combination studies, vol 58. Pharmacol Rev. American Society for Pharmacology and Experimental Therapeutics, pp 621–681. 3

Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375(19):1856–1867

Article  PubMed  PubMed Central  Google Scholar 

Cohen EEW, Soulières D, Tourneau C, Le et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156–167

Article  CAS  PubMed  Google Scholar 

Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928

Article  CAS  PubMed  Google Scholar 

Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising Oropharyngeal Cancer incidence in the United States. J Clin Oncol 29(32):4294–4301

Article  PubMed  PubMed Central  Google Scholar 

Dobler C, Jost T, Hecht M, Fietkau R, Distel L (2020) Senescence induction by combined Ionizing Radiation and DNA damage response inhibitors in Head and Neck squamous cell carcinoma cells. Cells 9(9):2012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen T, Yang F, Dai X et al (2023) VE-822 enhanced Cisplatin Chemotherapy effects on Head and Neck squamous cell Carcinoma Drug-resistant cells. Curr Cancer Drug Targets. ; 23

Shi Q, Shen L-Y, Dong B et al (2018) The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. Cancer Lett. Elsevier; ; 432(52):56–68. https://doi.org/10.1016/j.canlet.2018.06.010

Feng W, Dean DC, Hornicek FJ et al (2020) ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in Ovarian cancer. Ther Adv Med Oncol 12:175883592098285

Article  Google Scholar 

Baschnagel AM, Elnaggar JH, VanBeek HJ et al (2021) ATR inhibitor M6620 (VX-970) enhances the Effect of Radiation in non–small cell Lung Cancer Brain Metastasis patient-derived xenografts. Mol Cancer Ther 20(11):2129–2139

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni F, Tang H, Wang C et al (2019) Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system. Cancer Manag Res 11:8391–8405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi W, Xu X, Wang M et al (2019) Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem Pharmacol Elsevier 164(February):273–282

Article  CAS  Google Scholar 

Kim S, Il, Kang JW, Noh JK et al (2020) Gene signature for prediction of radiosensitivity in human papillomavirus-negative head and neck squamous cell carcinoma. Radiat Oncol J 38(2):99–108

Article  PubMed  PubMed Central  Google Scholar 

Leszczynska KB, Dobrynin G, Leslie RE et al (2016) Preclinical testing of an ATR inhibitor demonstrates improved response to standard therapies for Esophageal cancer. Radiother Oncol the Authors 121(2):232–238

Article  CAS  Google Scholar 

Liu C, Wang X, Qin W et al (2023) Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in Colorectal cancer. Cancer Commun. ; (February):435–454

Galluzzi L, Senovilla L, Vitale I et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene Nat Publishing Group 31(15):1869–1883

CAS  Google Scholar 

Wagner JM, Karnitz LM, Cisplatin-Induced DNA (2009) Damage activates replication Checkpoint Signaling Components that differentially affect Tumor Cell Survival. Mol Pharmacol 76(1):208–214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu A, Krishnamurthy S (2010) Cellular Responses to Cisplatin-Induced DNA Damage. J Nucleic Acids. ; 2010:1–16

Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-Deficient cells rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11(2):175–189

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall AB, Newsome D, Wang Y et al (2014) Potentiation of Tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5(14):5674–5685

Article  PubMed  PubMed Central  Google Scholar 

Liang X, Yang Q, Wang W, Liu T, Hu J (2019) VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response. Onco Targets Ther 12:6083–6092

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F (2011) ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene Nat Publishing Group 30(22):2526–2533

CAS  Google Scholar 

Bradford CR, Zhu S, Ogawa H et al (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25(8):654–661

Article  PubMed  Google Scholar 

Telli ML, Tolaney SM, Shapiro GI et al (2022) Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative Breast cancer. npj Breast Cancer 8(1):45

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kidiyoor GR, Li Q, Bastianello G et al (2020) ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration. Nat Commun Springer US 11(1):4828

Article  CAS